Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGAV | P06756 | 20/20 | 0.50 |
| ▸ | ITGB3 | P05106 | 16/20 | 0.50 |
| ▸ | ITGB5 | P18084 | 12/20 | 0.50 |
| ▸ | ITGB6 | P18564 | 12/20 | 0.50 |
| ▸ | ITGB8 | P26012 | 8/20 | 0.50 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20157743 | 0.93 | ITGAV (0.42) | ITGAVITGB3ITGB5ITGB6ITGB8 | |
| SCHEMBL20142850 | 0.89 | ITGB3 (0.48) | ITGAVITGB3ITGB5ITGB6ITGB8 | |
| SCHEMBL29701374 | 0.89 | ITGB3 (0.48) | ITGAVITGB3ITGB5ITGB6ITGB8 | |
| SCHEMBL20142853 | 0.89 | ITGB3 (0.48) | ITGAVITGB3ITGB5ITGB6ITGB8 | |
| SCHEMBL20158389 | 0.86 | ITGAV (0.66) | ITGAVITGB3ITGB5ITGB6ITGB8 | |
| SCHEMBL20157744 | 0.83 | ITGAV (0.69) | ITGAVITGB3ITGB5ITGB6ITGB8 | |
| SCHEMBL20142118 | 0.82 | ITGB3 (0.41) | ITGAVITGB3ITGB5ITGB6ITGB8 | |
| SCHEMBL21314490 | 0.82 | ITGB3 (0.41) | ITGAVITGB3ITGB5ITGB6ITGB8 | |
| SCHEMBL21272314 | 0.80 | ITGB3 (0.50) | ITGAVITGB3ITGB5ITGB6ITGB8 | |
| SCHEMBL21317527 | 0.79 | ITGAV (0.53) | ITGAVITGB3ITGB5ITGB6ITGB8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11639353-B2 | Cyclobutanes- and azetidine-containing mono and spirocyclic compounds as αV integrin inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-05-02 | — | — | US | disclosed |
| US-20210246136-A1 | CYCLOBUTANES- AND AZETIDINE-CONTAINING MONO AND SPIROCYCLIC COMPOUNDS AS ALPHA V INTEGRIN INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2021-08-12 | — | — | US | disclosed |
| US-11014922-B2 | Cyclobutane- and azetidine-containing mono and spirocyclic compounds as αV integrin inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-05-25 | — | — | US | disclosed |
| US-20190270741-A1 | CYCLOBUTANE- AND AZETIDINE-CONTAINING MONO AND SPIROCYCLIC COMPOUNDS AS ALPHA V INTEGRIN INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-09-05 | — | — | US | disclosed |
| WO-2018089355-A1 | CYCLOBUTANE- AND AZETIDINE-CONTAINING MONO AND SPIROCYCLIC COMPOUNDS AS ALPHA V INTEGRIN INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190270741-A1 | CYCLOBUTANE- AND AZETIDINE-CONTAINING MONO AND SPIROCYCLIC COMPOUNDS AS ALPHA V INTEGRIN INHIBITORS | ITGB1, ITGAV, ITGA1 | ITGAV 2/4885ITGB3 8/4885ITGB5 6/4885 |
| US-20210246136-A1 | CYCLOBUTANES- AND AZETIDINE-CONTAINING MONO AND SPIROCYCLIC COMPOUNDS AS ALPHA V INTEGRIN INHIBITORS | ITGB1, ITGAV, ITGA1 | ITGAV 2/4885ITGB3 7/4885ITGB5 6/4885 |
| US-11639353-B2 | Cyclobutanes- and azetidine-containing mono and spirocyclic compounds as αV integrin inhibitors | ITGB1, ITGB2, ITGA1 | ITGAV 4/4885ITGB3 6/4885ITGB5 7/4885 |
| US-11014922-B2 | Cyclobutane- and azetidine-containing mono and spirocyclic compounds as αV integrin inhibitors | ITGB1, ITGB2, ITGA1 | ITGAV 4/4885ITGB3 7/4885ITGB5 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.